We’ve recently updated our valuation analysis.

L&C Bio Valuation

Is A290650 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A290650?

Other financial metrics that can be useful for relative valuation.

A290650 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.7x
Enterprise Value/EBITDA39.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does A290650's PE Ratio compare to its peers?

The above table shows the PE ratio for A290650 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27x
A214450 PharmaResearch
16.6x16.9%₩772.1b
A005250 Green Cross Holdings
55.8xn/a₩750.4b
A377740 BioNote
2xn/a₩916.9b
A166480 CORESTEMCHEMON
33.7xn/a₩266.6b
A290650 L&C Bio
46.7xn/a₩518.3b

Price-To-Earnings vs Peers: A290650 is expensive based on its Price-To-Earnings Ratio (46.7x) compared to the peer average (27x).


Price to Earnings Ratio vs Industry

How does A290650's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a

Price-To-Earnings vs Industry: A290650 is expensive based on its Price-To-Earnings Ratio (46.7x) compared to the KR Biotechs industry average (24.1x)


Price to Earnings Ratio vs Fair Ratio

What is A290650's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A290650 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A290650's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of A290650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A290650 (₩22850) is trading above our estimate of fair value (₩932.84)

Significantly Below Fair Value: A290650 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies